These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 19148179)

  • 1. Prospects for improved bluetongue vaccines.
    Roy P; Boyce M; Noad R
    Nat Rev Microbiol; 2009 Feb; 7(2):120-8. PubMed ID: 19148179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccines against bluetongue in Europe.
    Savini G; MacLachlan NJ; Sanchez-Vizcaino JM; Zientara S
    Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):101-20. PubMed ID: 17765305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Replication-Deficient Particles: New Insights into the Next Generation of Bluetongue Virus Vaccines.
    Celma CC; Stewart M; Wernike K; Eschbaumer M; Gonzalez-Molleda L; Breard E; Schulz C; Hoffmann B; Haegeman A; De Clercq K; Zientara S; van Rijn PA; Beer M; Roy P
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bluetongue virus 'assembly kit' offers hope for improved vaccines.
    Vet Rec; 2011 Aug; 169(6):138. PubMed ID: 21821679
    [No Abstract]   [Full Text] [Related]  

  • 5. A monovalent attenuated serotype 2 bluetongue virus vaccine confers homologous protection in sheep.
    Hunter P; Modumo J
    Onderstepoort J Vet Res; 2001 Dec; 68(4):331-3. PubMed ID: 12026066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bluetongue virus without NS3/NS3a expression is not virulent and protects against virulent bluetongue virus challenge.
    Feenstra F; van Gennip RGP; Maris-Veldhuis M; Verheij E; van Rijn PA
    J Gen Virol; 2014 Sep; 95(Pt 9):2019-2029. PubMed ID: 24914064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From genes to complex structures of bluetongue virus and their efficacy as vaccines.
    Roy P
    Vet Microbiol; 1992 Nov; 33(1-4):155-68. PubMed ID: 1336237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccines for Prevention of Bluetongue and Epizootic Hemorrhagic Disease in Livestock: A North American Perspective.
    McVey DS; MacLachlan NJ
    Vector Borne Zoonotic Dis; 2015 Jun; 15(6):385-96. PubMed ID: 26086559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant vaccines against bluetongue virus.
    Calvo-Pinilla E; Castillo-Olivares J; Jabbar T; Ortego J; de la Poza F; Marín-López A
    Virus Res; 2014 Mar; 182():78-86. PubMed ID: 24287057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bluetongue--where are we now?
    Oura C
    Vet Rec; 2008 Oct; 163(16):491. PubMed ID: 18931359
    [No Abstract]   [Full Text] [Related]  

  • 11. Alternative methods to reduce the animal use in quality controls of inactivated BTV8 Bluetongue vaccines.
    Luciani M; Di Febo T; Ronchi GF; Sacchini F; Rossi E; Ulisse S; Di Pancrazio C; Antonucci D; Salini R; Teodori L; Podaliri Vulpiani M; Tittarelli M; Di Ventura M
    Prev Vet Med; 2020 Mar; 176():104923. PubMed ID: 32066029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA vaccine prime and recombinant FPV vaccine boost: an important candidate immunization strategy to control bluetongue virus type 1.
    Li J; Yang T; Xu Q; Sun E; Feng Y; Lv S; Zhang Q; Wang H; Wu D
    Appl Microbiol Biotechnol; 2015 Oct; 99(20):8643-52. PubMed ID: 26048472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant virus vaccine for bluetongue disease in sheep.
    Roy P; Urakawa T; Van Dijk AA; Erasmus BJ
    J Virol; 1990 May; 64(5):1998-2003. PubMed ID: 2157868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of bluetongue Disabled Infectious Single Animal (DISA) vaccine for different serotypes by VP2 exchange or incorporation of chimeric VP2.
    Feenstra F; Pap JS; van Rijn PA
    Vaccine; 2015 Feb; 33(6):812-8. PubMed ID: 25510389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bluetongue control--a new challenge for Europe.
    Makoschey B; Beer M; Zientara S; Haubruge E; Rinaldi L; Dercksen D; Millemann Y; von Rijn P; de Clercq K; Oura C; Saegerman C; Domingo M; Sanchez-Vizcaino JM; Mehlhorn H; Tamba M; Thiry E
    Berl Munch Tierarztl Wochenschr; 2008; 121(7-8):306-13. PubMed ID: 18712267
    [No Abstract]   [Full Text] [Related]  

  • 16. Supply of bluetongue vaccine.
    Bartram D
    Vet Rec; 2008 Mar; 162(12):387-8. PubMed ID: 18359934
    [No Abstract]   [Full Text] [Related]  

  • 17. Control of bluetongue in Europe.
    Zientara S; Sánchez-Vizcaíno JM
    Vet Microbiol; 2013 Jul; 165(1-2):33-7. PubMed ID: 23462519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scientific study of bluetongue vaccine uptake and efficacy.
    Wood J; Webb C; Oura C
    Vet Rec; 2008 Jun; 162(25):831. PubMed ID: 18567937
    [No Abstract]   [Full Text] [Related]  

  • 19. Bluetongue vaccines in Europe.
    Niedbalski W
    Pol J Vet Sci; 2011; 14(2):299-304. PubMed ID: 21721420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of protective immunity after a single vaccination with a live attenuated bivalent bluetongue vaccine.
    Zhugunissov K; Yershebulov Z; Barakbayev K; Bulatov Y; Taranov D; Amanova Z; Abduraimov Y
    Vet Res Commun; 2015 Dec; 39(4):203-10. PubMed ID: 26280208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.